Which medications in the drug class Interleukin Inhibitors are used in the treatment of Psoriatic Arthritis?

Updated: Jan 24, 2022
  • Author: Anwar Al Hammadi, MD, FRCPC; Chief Editor: Herbert S Diamond, MD  more...
  • Print
Answer

Interleukin Inhibitors

Interleukin (IL)-12/IL-23p40, IL-23, and IL-17 receptors are associated with inflammatory and immune responses in psoriatic arthritis. 

Ustekinumab (Stelara)

Ustekinumab is an anti-IL-12/23 monoclonal antibody approved for treatment of active psoriatic arthritis in adult patients. It may be administered alone or in combination with methotrexate. It is approved in doses of 45 mg or 90 mg SC given at weeks 0 and 4 and then every 12 weeks. 

Guselkumab (Tremfya)

Guselkumab is a human monoclonal antibody that selectively binds to IL-23 and inhibits its interaction with the IL-23 receptor. Therefore, it inhibits the release of proinflammatory cytokines and chemokines. It is indicated for active psoriatic arthritis in adults. It may be administered alone or in combination with a conventional DMARD (eg, methotrexate).

Ixekizumab (Taltz)

Humanized monoclonal IgG4 antibody that targets interleukin-17A (IL-17A) resulting in neutralization of IL-17A’s proinflammatory effects. It is indicated for adults with active psoriatic arthritis; may be administered alone or in combination with a conventional DMARD (eg, methotrexate).

Secukinumab (Cosentyx)

Human IgG1 monoclonal antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin 17A (IL-17A). IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It is indicated for adults and children aged 2 years and older with active psoriatic arthritis.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!